title: Effects of treatment of ectopic pregnancy with methotrexate or salpingectomy in the subsequent IVF cycle.
abstract: Ectopic pregnancy is a known risk for patients treated with IVF. The objective of this study was to evaluate the effect of methotrexate (MTX) and laparoscopic salpingectomy as treatments of ectopic pregnancy on ovarian response during IVF cycles. Data of all women treated for ectopic pregnancy as a result of IVF treatment were evaluated; the study included women who had an unruptured ectopic pregnancy after IVF treatment that was treated with either MTX or laparoscopic salpingectomy and underwent a subsequent IVF cycle. The main outcome measures were baseline serum FSH concentrations and ovarian response in the subsequent IVF cycle after treatment of ectopic pregnancy. Of a total of 58 patients, 36 were previously treated with MTX and 22 others by salpingectomy. No significant differences were observed between the MTX and the salpingectomy groups in the parameters of ovarian response in the subsequent IVF cycle.
authors.affiliation: Department of Obstetrics and Gynecology, McGill University Montreal, Quebec, Canada; Meir Medical Center, Kfar-Saba, Tel-Aviv University, Israel. amir.wiser@gmail.com
authors.forename: Amir
authors.initials: A
authors.lastname: Wiser
authors.forename: Audrey
authors.initials: A
authors.lastname: Gilbert
authors.forename: Ravit
authors.initials: R
authors.lastname: Nahum
authors.forename: Raoul
authors.initials: R
authors.lastname: Orvieto
authors.forename: Jigal
authors.initials: J
authors.lastname: Haas
authors.forename: Ariel
authors.initials: A
authors.lastname: Hourvitz
authors.forename: Ariel
authors.initials: A
authors.lastname: Weissman
authors.forename: Grace
authors.initials: G
authors.lastname: Younes
authors.forename: Martha
authors.initials: M
authors.lastname: Dirnfeld
authors.forename: Anat
authors.initials: A
authors.lastname: Hershko
authors.forename: Adrian
authors.initials: A
authors.lastname: Shulman
authors.forename: Avi
authors.initials: A
authors.lastname: Tsafrir
authors.forename: Hananel
authors.initials: H
authors.lastname: Holzer
authors.forename: Einat
authors.initials: E
authors.lastname: Shalom-Paz
authors.forename: Togas
authors.initials: T
authors.lastname: Tulandi
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D015415:Biomarkers / Q000097:blood; D006063:Chorionic Gonadotropin / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D008727:Methotrexate / Q000494:pharmacology / Q000627:therapeutic use*; D010053:Ovary / Q000187:drug effects / Q000502:physiology; D010062:Ovulation Induction; D011247:Pregnancy; D011256:Pregnancy Outcome; D011271:Pregnancy, Ectopic / Q000628:therapy*; D012189:Retrospective Studies; D058994:Salpingectomy; D016896:Treatment Outcome
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D015415:Biomarkers; D006063:Chorionic Gonadotropin; D008727:Methotrexate